Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. more
Time Frame | NRBO | Sector | S&P500 |
---|
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | 7.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 17.00K | 67.00K | 72.00K | 28.00K | 7.00K | [{"date":"2019-12-31","value":23.61,"profit":true},{"date":"2020-12-31","value":93.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":38.89,"profit":true},{"date":"2023-12-31","value":9.72,"profit":true}] |
Gross Profit | (17.00K) | (67.00K) | (72.00K) | (28.00K) | - | [{"date":"2019-12-31","value":-1700000,"profit":false},{"date":"2020-12-31","value":-6700000,"profit":false},{"date":"2021-12-31","value":-7200000,"profit":false},{"date":"2022-12-31","value":-2800000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | - | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 20.18M | 29.72M | 15.30M | 11.42M | 15.89M | [{"date":"2019-12-31","value":67.9,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":51.48,"profit":true},{"date":"2022-12-31","value":38.42,"profit":true},{"date":"2023-12-31","value":53.46,"profit":true}] |
Operating Income | (20.18M) | (29.72M) | (15.30M) | (19.63M) | (15.89M) | [{"date":"2019-12-31","value":-2017600000,"profit":false},{"date":"2020-12-31","value":-2971600000,"profit":false},{"date":"2021-12-31","value":-1529800000,"profit":false},{"date":"2022-12-31","value":-1962800000,"profit":false},{"date":"2023-12-31","value":-1588600000,"profit":false}] |
Total Non-Operating Income/Expense | (1.16M) | 77.00K | 28.00K | 3.47M | 1.39M | [{"date":"2019-12-31","value":-33.37,"profit":false},{"date":"2020-12-31","value":2.22,"profit":true},{"date":"2021-12-31","value":0.81,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":39.97,"profit":true}] |
Pre-Tax Income | (21.31M) | (29.68M) | (15.28M) | (13.97M) | (12.47M) | [{"date":"2019-12-31","value":-2131200000,"profit":false},{"date":"2020-12-31","value":-2967800000,"profit":false},{"date":"2021-12-31","value":-1528400000,"profit":false},{"date":"2022-12-31","value":-1396700000,"profit":false},{"date":"2023-12-31","value":-1247000000,"profit":false}] |
Income Taxes | 1.12M | (85.00K) | (62.00K) | (7.85M) | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-7.6,"profit":false},{"date":"2021-12-31","value":-5.54,"profit":false},{"date":"2022-12-31","value":-701.7,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (22.43M) | (29.59M) | (15.22M) | (6.12M) | - | [{"date":"2019-12-31","value":-2243100000,"profit":false},{"date":"2020-12-31","value":-2959300000,"profit":false},{"date":"2021-12-31","value":-1522200000,"profit":false},{"date":"2022-12-31","value":-611500000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (21.31M) | (29.68M) | (15.28M) | (13.97M) | (11.83M) | [{"date":"2019-12-31","value":-2131200000,"profit":false},{"date":"2020-12-31","value":-2967800000,"profit":false},{"date":"2021-12-31","value":-1528400000,"profit":false},{"date":"2022-12-31","value":-1396700000,"profit":false},{"date":"2023-12-31","value":-1183200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (22.43M) | (29.59M) | (15.22M) | (6.12M) | (12.47M) | [{"date":"2019-12-31","value":-2243100000,"profit":false},{"date":"2020-12-31","value":-2959300000,"profit":false},{"date":"2021-12-31","value":-1522200000,"profit":false},{"date":"2022-12-31","value":-611500000,"profit":false},{"date":"2023-12-31","value":-1247000000,"profit":false}] |
EPS (Diluted) | (263.85) | (55.20) | (51.39) | (5.61) | (2.49) | [{"date":"2019-12-31","value":-26385,"profit":false},{"date":"2020-12-31","value":-5520,"profit":false},{"date":"2021-12-31","value":-5139,"profit":false},{"date":"2022-12-31","value":-561,"profit":false},{"date":"2023-12-31","value":-249,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
NRBO | |
---|---|
Cash Ratio | 2.38 |
Current Ratio | 2.41 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NRBO | |
---|---|
ROA (LTM) | -74.35% |
ROE (LTM) | -160.76% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NRBO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.42 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.58 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NRBO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.36 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Neurobo Pharmaceuticals Inc (NRBO) share price today is $
Yes, Indians can buy shares of Neurobo Pharmaceuticals Inc (NRBO) on Vested. To buy Neurobo Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NRBO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Neurobo Pharmaceuticals Inc (NRBO) via the Vested app. You can start investing in Neurobo Pharmaceuticals Inc (NRBO) with a minimum investment of $1.
You can invest in shares of Neurobo Pharmaceuticals Inc (NRBO) via Vested in three simple steps:
The 52-week high price of Neurobo Pharmaceuticals Inc (NRBO) is $6.75. The 52-week low price of Neurobo Pharmaceuticals Inc (NRBO) is $1.51.
The price-to-earnings (P/E) ratio of Neurobo Pharmaceuticals Inc (NRBO) is
The price-to-book (P/B) ratio of Neurobo Pharmaceuticals Inc (NRBO) is 1.36
The dividend yield of Neurobo Pharmaceuticals Inc (NRBO) is 0.00%
The market capitalization of Neurobo Pharmaceuticals Inc (NRBO) is $20.33M
The stock symbol (or ticker) of Neurobo Pharmaceuticals Inc is NRBO